Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TYRA
SELLTyra Biosciences, Inc. · Healthcare · United States · $1.8B · Avg Vol: $27M/d
COMPANY DESCRIPTION
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for patients with a variety of cancers, particularly those with acquired resistance to existing therapies. The company's competitive moat is underpinned by its proprietary SNF platform, enabling the discovery of highly selective small molecule inhibitors targeting resistance mutations in oncology. Tyra Biosciences is positioned as an innovator in addressing the challenge of drug resistance in cancer treatment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 3.1M | — |
| EPS | -1.32 | -1.62 | -1.51 | -2.01 | — | -2.11 | -2.57 | -2.86 | — |
| Shares | 42.4M | 43.0M | 50.7M | 53.7M | +26.8% | 59.5M | — | — | — |
| Debt | 2.6M | 6.5M | 6.2M | 5.8M | 30.4% | 5.7M | — | — | — |
| Equity | 257.8M | 204.3M | 343.2M | 259.2M | 0.2% | — | — | — | — |
| Op CF | -50.3M | -50.1M | -69.8M | -95.1M | — | -102.3M | — | — | — |
| Inv CF | -0.6M | -144.6M | -98.4M | 72.5M | — | — | — | — | — |
| Fin CF | 0.6M | 1.5M | 202.1M | 8.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TYRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TYRA | Tyra Biosciences, Inc.(you) | $1.8B | 20 | SELL |
| ZYME | Zymeworks Inc. | $1.7B | 19 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 17 | STRONG SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| BHVN | Biohaven Ltd. | $2.2B | 19 | STRONG SELL |
| TSHA | Taysha Gene Therapies, Inc. | $1.6B | 18 | STRONG SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 16 | STRONG SELL |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.9B | 25 | SELL |
| STOK | Stoke Therapeutics, Inc. | $1.8B | 26 | SELL |
| MPLT | MapLight Therapeutics, Inc. | $1.7B | 25 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%